ACET Stock Summary and Trading Ideas (Adicet Bio | NASDAQ:ACET)

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio trades on the NASDAQ stock market under the symbol ACET.

As of January 14, 2025, ACET stock price climbed to $0.91 with 371,578 million shares trading.

ACET has a beta of 2.11, meaning it tends to be more sensitive to market movements. ACET has a correlation of 0.06 to the broad based SPY ETF.

ACET has a market cap of $74.92 million. This is considered a Micro Cap stock.

In the last 3 years, ACET traded as high as $21.87 and as low as $.81.

The top ETF exchange traded funds that ACET belongs to (by Net Assets): VTI, VXF, FESM, IWC, CNCR.

ACET has underperformed the market in the last year with a return of -72.7%, while the SPY ETF gained +23.6%. In the last 3 month period, ACET fell short of the market, returning -34.6%, while SPY returned +0.8%. However, in the most recent 2 weeks ACET has outperformed the stock market by returning +0.9%, while SPY returned -1.0%.

ACET support price is $.82 and resistance is $.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACET shares will trade within this expected range on the day.